Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 10 other studies
1,708people in the Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus trial, from 2019
636of them with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
liraglutide
control group
Probably lowered stroke recurrence after 90 days−44%
Probably raised excellent functional outcomes1.9×
randomisedthe abstract, start to end
… stroke recurrence (hazard ratio, 0.56; 95% CI, 0.34-0.91; P = .02).
… functional outcomes (odds ratio, 1.95; 95% CI, 1.28-3.00; P = .002).
← favours treatmentfavours comparator →
could be chanceStroke recurrence (ischemic or hemorrhagic) after 90 daysliraglutide vs control group
HR 0.560.34–0.91
Excellent functional outcomes (modified Rankin Scale score, ≤1)liraglutide vs control group
OR 1.951.28–3.00
GLP-1 receptor agonistsCardiovascular eventsAdverse events & safety
GLP-1 receptor agonists × cardiovascular eventshelps?mixed
unlikelylikely
0.500.78 without it
GLP-1 receptor agonists × adverse events & safetyharms?mixed
unlikelylikely
0.020.02 without it
← favours treatmentfavours comparator →
1 / 6